TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Percheron Therapeutics ( (AU:PER) ) has issued an announcement.
Percheron Therapeutics has made significant progress in the development of its lead anti-cancer program, HMBD-002, following the technology transfer from Hummingbird Bioscience. The company has assumed full responsibility for the drug’s development, including regulatory and intellectual property matters, and is preparing for a phase II clinical trial. The recent strengthening of its executive team and consultations with leading scientists and clinicians highlight Percheron’s commitment to advancing HMBD-002’s clinical development. The company plans to share phase I trial results and an overview of the phase II study design with investors, signaling a clear path forward for this promising cancer therapy.
The most recent analyst rating on (AU:PER) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for oncology and rare diseases. The company is actively involved in the research and development of innovative cancer treatments, with a particular focus on immunotherapies.
Average Trading Volume: 3,061,336
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
Learn more about PER stock on TipRanks’ Stock Analysis page.